Treatment of Pediatric IBD: What is Different?

January 13, 2017

Michael Kappelman MD, MPH
University of North Carolina at Chapel Hill
Overview

- Is Pediatric IBD the same disease?
- Treatment considerations
Overview

• Is pediatric IBD the same disease?
  – Epidemiology
  – Presentation and symptoms
  – Phenotype and natural history

• Treatment considerations
Epidemiology: Pediatric IBD is a rare disease

Overall incidence: 9.5 per 100,000
CD twice as common as UC in childhood
Both CD and UC very rare prior to age 6, with sharp increase thereafter
Slight male predominance for both diseases, especially CD

Adamiak, Inflamm Bow Dis, 2013
Prevalence: Pediatric IBD

- Prevalence Estimates from US Commercially Insured population (< age 20)
  - Crohn’s disease: 58 per 100K
  - Ulcerative Colitis: 34 per 100K

- Extrapolation to US population
  - Crohn’s disease: 38K
  - Ulcerative Colitis: 23K

- ~5% of IBD patients in the U.S. are children

- Classified as “rare diseases” by NIH
  - FDA Orphan Drug Designation

Kappelman, DDaS, 2013
<table>
<thead>
<tr>
<th>Common Presentations of Pediatric IBD</th>
<th>Crohn’s disease (n=386)</th>
<th>Ulcerative colitis (n=195)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain - 86%</td>
<td>Abdominal pain 69%</td>
<td></td>
</tr>
<tr>
<td>Diarrhea - 78%</td>
<td>Diarrhea – 93%</td>
<td></td>
</tr>
<tr>
<td>Blood in stool - 49%</td>
<td>Blood in stool – 95%</td>
<td></td>
</tr>
<tr>
<td>Weight loss – 80%</td>
<td>Weight loss – 55%</td>
<td></td>
</tr>
<tr>
<td>Fever – 38%</td>
<td>Fever – 15%</td>
<td></td>
</tr>
<tr>
<td>Perianal lesions – 44%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
What’s different: Growth

- ~ 3% patients present with growth failure as predominant symptom
- More common in CD than in UC
- Adult height compromised
  - CD: 32-88%
  - UC: 9-34%
- Etiology of growth failure
  - Intestinal inflammation
  - Inadequate oral intake
  - Diarrhea and nutrient losses
  - Steroids
What’s different: Bone Health

- Maximum accumulation of calcium in your bones occurs in mid-teen years.
- Decreased bone mineral density common in children and adolescents with IBD
- Etiology multifactorial
  - Poor calcium absorption/intake; vitamin D deficiency
  - Decreased physical activity
  - Inflammation
  - Steroid use
What’s different: Pubertal Delay

• Pubertal delay in ~1/4 of children with CD
  – Delay usually 6-12 months

• Pubertal delay much less frequent in UC
What’s different: psychosocial impact

- Psychosocial impact of IBD well-appreciated in adults
- Effects compounded in pediatrics
  - Being a teen is hard enough!
  - Being different (having a chronic illness) makes it tougher
  - Embarrassing symptoms/steroid side effects impact self-image
  - Complicated medical/dietary regimens, procedures, frequent clinic visits, and hospitalizations are all added stressors

- Depression well described in children with IBD
  (Szigethy et al. 2004 and 2014. JPGN)

- Children with IBD have poorer school functioning compared to healthy children
Phenotype and Natural History: CD

- More extensive disease distribution
  - 69% with L3 at dx; 82% at max follow-up
  - 36% UGI at dx; 48% at max follow up

- Behavior: B1 predominant
  - At 5 years
    - Pediatric: 73%
    - Adult: 66%

Vernier-Massouille, Gastro, 2008
Van Limbergen, Gastro, 2008
Surgery in Pediatric CD

• Cumulative probability of surgery by 5 years
  – 20% pediatric onset
  – 43% adult onset

• Time to surgery greater in pediatric vs adult CD
  – ? More extensive distribution less amenable to surgery
  – > B1 (inflammatory)

Van Limbergen, Gastro, 2008
Phenotype and Natural History: UC

• More extensive disease distribution
  – Ped UC: 82% with pancolitis at max follow-up
  – Adult UC: 48% pancolitis at max follow-up

• Colectomy by 5 years
  – 26% pediatric onset
  – 16% adult onset

Van Limbergen, Gastro, 2008
Pediatric vs Adult IBD: Different diseases?

• Pediatric IBD rare disease
  – Orphan drug implications

• Gastrointestinal and EI symptoms similar
  – Unique developmental aspects of pediatric IBD:
    • growth and pubertal delay
    • diminished bone density
    • psychosocial impact

• Disease extent often greater in pediatric IBD

• CD: more often inflammatory; less surgery

• UC: higher need for colectomy
Overview

• Is pediatric IBD the same disease?
• Treatment considerations
Treatment Considerations

- Available treatment options largely the same
  - Greater off-label use
  - Sometimes a barrier for insurance authorization
- As with adults, treatment decisions involve balancing the risks and benefits
  - Including risks of un/under-treated IBD
- General treatment considerations underscore differences between pediatric and adult IBD
Consideration #1: Urgency of Treatment

- Children experience life faster
  - Greater consequences of “missing out” due to illness
- Finite “window” for development
  - Growth
  - Bone mineral density
  - Psychosocial
- Urgent need to commence effective medical therapy!
Consideration #2: Avoidance of steroids

- Steroid side effects compounded in pediatrics
  - Growth
  - Bone density
  - Appearance (acne, cushingoid)
    - Kids particularly sensitive to body image
  - Other psychosocial effects

In general, pediatric IBD patients have a greater need to achieve rapid disease control with steroid-sparing
Consideration #3: Treatment Effectiveness

- Medical treatment may be more effective in pediatric IBD
  - Shorter disease duration
  - For CD:
    - More “inflammatory” disease

<table>
<thead>
<tr>
<th>Population</th>
<th>Study</th>
<th>Disease duration (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td>ACCENT I (infliximab)</td>
<td>7.9</td>
</tr>
<tr>
<td>Pediatric</td>
<td>REACH (infliximab)</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Hanauer, Lancet, 2002
Hyams, Gastro, 2007
Effectiveness of anti-TNF

- **Clinical Remission (%)**
  - **Week 10**
  - **Week 26**

**Infliximab**
- Pediatric: 50%
- Adult: 40%

**Adalimumab**
- Pediatric: 50%
- Adult: 40%

Data from **ACCENT I and REACH**
Different study designs; outcome measures

Data from **CHARM and IMAgINE 1**
Different study designs, Ped data converted to CDAI of week 4 response; CHARM only in week 4 responders

Hanauer, Lancet, 2002
Hyams, Gastro, 2007
Colombel, Gastro, 2007
Hyams, Gastro, 2012
Consideration #3: Extent of disease

- Disease location more extensive in pediatric IBD
- Limits effectiveness of topical agents
  - Ileal release budesonide for Crohn’s
  - Topical rectal therapy in UC
Consideration #4: Treatment Outcomes

• As in adult IBD, treatment outcomes include:
  – Improving GI and EI symptoms
  – Normalizing laboratory abnormalities (hgb, alb, crp, esr)
  – Nutritional status
  – Mucosal healing

• Pediatric specific outcomes:
  – Growth
  – Bone density
  – Psychosocial
Effective Treatment Improves Growth

**Methotrexate**

- 1 yr pre-MTX
- 1 yr post-MTX

**Infliximab**

- Good 1-year response (N = 36)
- Poor or partial 1-year response (N = 24)

**Adalimumab**

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height Velocity Z score</td>
<td>-0.4</td>
<td>2</td>
</tr>
</tbody>
</table>

Turner, AJG, 2007
Hyams, Gastro, 2012
Walters, AIBD, Dec 2006
Effective Treatment Improves Growth

- **Methotrexate**
- **Infliximab**
- **Adalimumab**

- Effective treatment also improves bone health and psychological functioning

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height Velocity Z score</td>
<td>-0.4</td>
<td>2</td>
</tr>
</tbody>
</table>

Turner, AJG, 2007
Hyams, Gastro, 2012
Walters, AIBD, Dec 2006
Consideration #5: Different risks

• Treatment decisions should be made based on absolute risk
  – Not relative risk

• Absolute risk of many treatments may be less in children
  – Risk of serious infection and malignancy increase with age in general population
  – Comorbidities less frequent in children
Infections: Herpes Zoster

Figure 2: Incidence of Zoster by Age in CD, UC and non-IBD populations

Long, Aliment Pharmacol Ther, 2013
Lymphoma-background incidence

Non-Hodgkin Lymphoma
SEER Incidence by Age
All Races, Males

Rate per 100,000

Age at Diagnosis

Kotlyar DS, CGH, 2015
### NNH vs background incidence

Number Needed to Treat (Harm) to Cause 1 Additional Lymphoma per Year

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Lymphoma incidence(^{a,b})</th>
<th>NNH if relative risk of lymphoma = 2</th>
<th>NNH if relative risk of lymphoma = 3</th>
<th>NNH if relative risk of lymphoma = 4</th>
<th>NNH if relative risk of lymphoma = 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–29</td>
<td>7.25</td>
<td>6897</td>
<td>4598</td>
<td>3448</td>
<td>2759</td>
</tr>
<tr>
<td>30–39</td>
<td>9.45</td>
<td>5291</td>
<td>3527</td>
<td>2646</td>
<td>2116</td>
</tr>
<tr>
<td>40–49</td>
<td>15.6</td>
<td>3205</td>
<td>2137</td>
<td>1603</td>
<td>1282</td>
</tr>
<tr>
<td>50–59</td>
<td>29.9</td>
<td>1672</td>
<td>1115</td>
<td>836</td>
<td>669</td>
</tr>
<tr>
<td>60–69</td>
<td>59.0</td>
<td>848</td>
<td>565</td>
<td>424</td>
<td>339</td>
</tr>
<tr>
<td>70–79</td>
<td>102.5</td>
<td>488</td>
<td>325</td>
<td>244</td>
<td>195</td>
</tr>
</tbody>
</table>

Kotlyar DS, CGH, 2015
<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Lymphoma incidence(^{a,b})</th>
<th>NNH if relative risk of lymphoma = 2</th>
<th>NNH if relative risk of lymphoma = 3</th>
<th>NNH if relative risk of lymphoma = 4</th>
<th>NNH if relative risk of lymphoma = 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–29</td>
<td>7.25</td>
<td>6897</td>
<td>4598</td>
<td>3448</td>
<td>2759</td>
</tr>
<tr>
<td>30–39</td>
<td>9.45</td>
<td>5291</td>
<td>3527</td>
<td>2646</td>
<td>2116</td>
</tr>
<tr>
<td>40–49</td>
<td>15.6</td>
<td>3205</td>
<td>2137</td>
<td>1603</td>
<td>1282</td>
</tr>
<tr>
<td>50–59</td>
<td>29.9</td>
<td>1672</td>
<td>1115</td>
<td>836</td>
<td>669</td>
</tr>
<tr>
<td>60–69</td>
<td>59.0</td>
<td>848</td>
<td>565</td>
<td>424</td>
<td>339</td>
</tr>
<tr>
<td>70–79</td>
<td>102.5</td>
<td>488</td>
<td>325</td>
<td>244</td>
<td>195</td>
</tr>
</tbody>
</table>

Kotlyar DS, CGH, 2015
Exception: HSTCL

Hepatosplenic T cell lymphoma

- Rare, often fatal
- Male predominant (>90%)
- 17/25 cases (68%) < 35 years of age
- Most reported case on combination therapy with thiopurine + anti-TNF
Consideration #6: Greater focus on nutrition

• Increased attention to:
  – nutrition, growth, skeletal health
  – corticosteroid avoidance

• Nutritional therapy more widely utilized in pediatric IBD
Enteral Therapy in Crohn’s Disease

- Effective in children and adults with Crohn’s disease for induction and maintenance (50-75%)
- EEN vs. corticosteroids (peds)
  - Better remission rates
  - Positive effect on growth
  - Mucosal healing
- EEN may be more effective in children than adults
- Efficacy not demonstrated in UC

Gupta. et al (2013). Inflamm Bowel Dis
Consideration #7: Limited data

• Even in 2017, many important treatment decisions in pediatric IBD are made with limited data!
  – Few well-designed clinical trials
  – Some multi-center cohorts
  – Many single-center retrospective reports
• Much extrapolation from adult data
• We need more high-quality pediatric clinical trials
• Pediatric IBD community is very invested
  – Well established multi-center collaborations
• We can pull this off!
PRO-KIIDS and Risk

• PRO-KIIDS
  – CCFA sponsored Pediatric IBD Research Network
  – ~ 30 participating centers

• Risk
  – Inception cohort to identify the genetic, microbiological, and immunological factors predictive of more severe CD
  – ~1,100 children from 28 centers recruited before diagnosis
  – Primary manuscript now in press at major medical journal
ImproveCareNow

- Learning health network of 95 centers
  - Point of care data collection
  - > 26K patients and 170K visits
  - Largest and fastest growing pediatric IBD registry
- Use of quality improvement to continuously measure and optimize site performance
- Registry to facilitate research
- Increasing focus on communication, engagement, and community building
Summary

• Epidemiological, clinical, and phenotypic differences between pediatric and adult IBD
• Treatment options largely the same
• A number of developmental-specific treatment considerations may (slightly) shift the risk-benefit equation
• More pediatric research urgently needed
• **As a community, we have the will and infrastructure to do it!**